Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
NCT00193596
Completed
In this randomized trial, we will investigate the activity and toxicity of two active regimens, gemcitabine/irinotecan and paclitaxel/carboplatin/Etoposide (both followed by ZD1839) in the first-line treatment of patients with carcinoma of unknown primary site.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2013
Locations: Methodist Cancer Center, Omaha, Nebraska
Conditions: Neoplasms, Unknown Primary
Register for Updates
S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
NCT00004011
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if surgery plus combination chemotherapy is more effective than surgery alone for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of surgery with or without combination chemotherapy in treating patients who have non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2013
Locations: CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska +2 locations
Conditions: Lung Cancer
Register for Updates
Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
NCT00294762
Completed
This will be the first prospective study where patients will be selected on the basis of two measures of the epidermal growth factor receptor (EGFR) pathway. The study will assess prospectively the efficacy of erlotinib as a single agent or intercalated with chemotherapy in highly selected patients with EGFR overexpression and/or EGFR amplification.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2012
Locations: Alegent Healthcare, Omaha, Nebraska
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer
NCT00102973
Completed
The purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer, that is refractory or resistant to platinum chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/30/2012
Locations: Alegent Health Immanuel Medical Center, Omaha, Nebraska +5 locations
Conditions: Ovarian Neoplasms
Register for Updates
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
NCT00356525
Terminated
The purpose of this study is to help answer: * Whether pemetrexed, gemcitabine and/or carboplatin can shrink tumor(s) or make tumor(s) disappear in patients with relapsed lung cancer (lung cancer that has come back after surgical removal and chemotherapy), and to determine how long this will last * Whether pemetrexed, gemcitabine and/or carboplatin can help patients with relapsed lung cancer live longer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2010
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska
Conditions: Lung Neoplasms
Register for Updates